Ken Griffin Alaunos Therapeutics, Inc. Call Options Transaction History

Citadel Advisors LLC

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2023 Feb 14, 2024	SELL	$0.04 - $0.13 $32 - $104	-800 Reduced 0.64%	125,100 $8,000
Q3 2023 Nov 14, 2023	SELL	$0.12 - $0.5 $7,884 - $32,850	-65,700 Reduced 34.29%	125,900 $16,000
Q2 2023 Aug 14, 2023	SELL	$0.43 - $0.65 $9,288 - $14,040	-21,600 Reduced 10.13%	191,600 $97,000
Q1 2023 May 15, 2023	BUY	$0.46 - $0.81 $13,294 - $23,409	28,900 Added 15.68%	213,200 $134,000
Q4 2022 Feb 14, 2023	BUY	$0.5 - $261.0 $33,450 - $17.5 Million	66,900 Added 56.98%	184,300 $119,000
Q3 2022 Nov 14, 2022	SELL	$1.04 - $322.5 $28,392 - $8.8 Million	-27,300 Reduced 18.87%	117,400 $202,000

92.6K

Ticker TCRT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 216,182,000
Market Cap $458M
Description
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancrea...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.